Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Medicines Agency's CHMP issues positive opinion on GlaxoSmithKline Plc and Pfizer Inc ViiV Healthcare's Triumeq single-tablet regimen


Friday, 27 Jun 2014 09:33am EDT 

GlaxoSmithKline Plc:ViiV Healthcare, global specialist HIV company established by GlaxoSmithKline and Pfizer, says committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has issues positive opinion recommending marketing authorisation.Issues for Triumeq (dolutegravir/abacavir/lamivudine) for treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg. 

Company Quote

45.79
0.43 +0.95%
24 Oct 2014